You are here

Home » Content

Venöz Mikroanastomoza Eritropoietinin Etkileri

The Effects of Erythropoietin on Venous Microanastomosis

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Although microsurgery has rapid advanced, problems at the site of venous microanastomosis still continue. Thrombosis of the venous microanastomosis is the major reason for free tissue transfer and replantation complications. Erythropoietin is a principal hematopoietic regulator responsible for the proliferation and diferentiation of erythroid progenitor cells and endothelial cells. Aim of this study is to observe the complications of microvenous anastomosis line and to investigate the protective effects of erythropoietin. Seventy eight Sprague-Dawley rats were divided into two groups (Control and Erythropoietin), and the groups were subdivided into three groups (3rd, 5th and 7th days). Rat dorsal penil vein was the study model. One-hundred-fifty IU/kg Erythropoietin was administrated via subcutaneously instantly venous anastomosis and every 48 hours to all Erythropoietin groups. Penil vein anastomosis line samples and blood samples were taken for assesment at 3rd, 5th and 7th days, after venous anastomosis. Morphometric analysis of each venous segment was done with a Clemex analysis program by the same examiner. Neointimal and medial areas were measured in each section and the neointima/media ratio was calculated. Haematocrit values were measured in all rats for 3rd, 5th and 7th days. The ratio of intima to medial areas were significantly less in Erythropoietin groups for 3rd and 5th days compared to control groups for the same days. There were no significant difference for the ratio of intima to medial areas between the contol and erythropoietin groups for 7th day. There were no significant difference for haematocrit levels between the the control and erythropoietin groups at 3rd, 5th and 7th days. Our study has shown that erythropoietin administration markedly reduced intimal formation and risk of thrombosis with accelerated endothelial regeneration after microvascular anastomosis in rat dorsal penil vein.
Bookmark/Search this post with
Abstract (Original Language): 
Mikrocerrahide hızlı ilerlemeler olmasına rağmen venöz mikroanastomoz alanındaki problemler hala devam etmektedir. Serbest doku transferleri ve replantasyon komplikasyonlarının major nedeni venöz mikroanastomoz trombozudur. Eritropoietin, eritroid progenitor ve endotelyal hücrelerin proliferasyonu ve farklılaşmasından sorumlu en önemli hematopoietik düzenleyicidir. Bu çalışmanın amacı venöz mikroanastomoz alanındaki komplikasyonları gözlemlemek ve eritropoetinin buna karşı koruyucu etkisini araştırmaktır. Yetmiş sekiz adet Sprague- Dawley cinsi erkek rat kontrol ve eritropoietin olarak iki gruba ayrıldı; bu iki grup da 3., 5. ve 7. gün olmak üzere üç alt gruba ayrıldı. Çalışma modeli olarak rat dorsal penil veni kullanıldı. Tüm eritropoietin gruplarına anastomoz anında ve her 48 saatte bir 150 IU/kg dozda eritropoietin uygulandı. Venöz anastomoz sonrası 3., 5. ve 7. günlerde değerlendirilmek üzere penil ven anastomoz hattı ve kan örnekleri alındı. Her bir venöz segmentin morfometrik analizi aynı araştırıcı tarafından Clemex® analiz programı ile yapılarak neointima ve media alanları ölçüldü ve neointima/media oranları hesaplandı. 3., 5. ve 7. günlerde tüm ratların hematokrit değerleri ölçüldü. 3. ve 5. günlerde eritropoietin gruplarında kontrol gruplarına göre intima/media oranları anlamlı derecede daha düşük bulundu. 7. gün için kontrol ve eritropoietin grupları arasında anlamlı fark bulunmadı. Hematokrit değerleri için 3., 5. ve 7. günlerde kontrol ve eritropoietin grupları arasında fark bulunmadı. Çalışmamız rat dorsal penil veninde mikrovasküler anastomoz sonrası eritropoietin uygulamasının endotelyal rejenerasyonu hızlandırarak intimal formasyonu ve trombüs riskini önemli derecede azalttığını göstermiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-venoz-mikroanastomoza-eritropoietinin-etkileri.pdf
  • 2
49-53
  • Turkish

REFERENCES

References: 

1- Griffin JR, Thornton JF. Microsurgery: Free tissue transfer and replantation.
Selected Readings in Plastic Surgery 2005;10:1-39.
2- Hjortdal VE, Sinclair T, Kerrigan CL, Solymoss S. Arterial ischemia in
skin flaps: microcirculatory intravascular thrombosis. Plast Reconstr Surg
1994;93:375-85.
3- Gu YD, Li JF, Jiang JF, Zhong CS, Tang PZ. Scanning electron microscopic
bservations on the endothelial healing mechanism of vessels. J Reconstr
Microsurg 1989;5:327-30.
4- Albanese V, Spadaro A, Tomasello F, Conforti P. Dynamics of endothelial
repair in end-to-side microsurgical carotid anastomoses in rats: a scanning
electron microscopic evaluation. Neurol Res 1981;3:267-87.
5- Muramatsu K, Shigetomi M, Ihara K, Kawai S, Doi K. Vascular complication
in free tissue transfer to the leg. Microsurgery 2001;21:362-5.
6- Kroll SS, Schusterman MA, Reece GP, Miller MJ, Evans GR, Robb GL,
Baldwin BJ. Timing of pedicle thrombosis and flap loss after free-tissue
transfer. Plast Reconstr Surg 1996;98:1230- 1233.
7- Bonde CT, Heslet L, Jansen E, Elberg JJ. Salvage of free flaps after venous
thrombosis: case report. Microsurgery 2004;24:298-301.
8- Yajima H, Tamai S, Mizumoto S, Ono H, Fukui A. Vascular complications of
vascularized composite tissue transfer: outcome and salvage techniques.
Microsurgery 1993;14:473-8
9- Sasaki R, Masuda S, Nagao M. Erythropoietin: multiple physiological
functions and regulation of biosynthesis. Biosci Biotechnol Biochem
2000;64:1775-93.
10- Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, et al.
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell
mobilization Blood 2003:15;102:1340-6.
11- Kling PJ, Sullivan TM, Roberts RA, Philipps AF, Koldovsky O. Human milk
as a potential enteral source of erythropoietin. Pediatr Res 1998;43:216-21.
12- Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P, Nico B, Roncali L,
Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in
cultured endothelial cells and stimulates neovascularization in vivo. Blood
1999;15: 2627-36.
13- Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT.
Erythropoietin receptor mRNA expression in human endothelial cells. Proc
Natl Acad Sci U S A 1994;91:3974-8.
14- Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B et al.
Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-6.
15- Kroll SS, Schusterman MA, Reece GP, Miller MJ, Evans GR, Robb GL,
Baldwin BJ. Timing of pedicle thrombosis and flap loss after free-tissue
transfer. Plast Reconstr Surg 1996;98:1230-3.
16- Borg ED, Werker PM, Franken RJ, Borst C, Kon M. Effect of vascular
freezing on the histopathology of dissected small vessels in the rat:
vascular freezing does induce intimal hyperplasia in arteries and veins.
Microsurgery 2000;20:331-6
17- Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T et
al. Statin therapy accelerates reendothelialization a novel effect involving
mobilization and incorporation of bone marrow-derived endothelial
progenitor cells. Circulation 2002;105:3017-24.
18- Six I, Van Belle E, Bordet R, et al. L- Arginine and L-Name have no
effects on the reendothelialization process after arterial balloon injury.
Cardiovascular research 1999;43:731-8.
19- Lee CW, Park SJ, Park SW, Kim JJ, Hong MK, Song JK. All-trans-retinoic
acid attenuates neointima formation with acceleration of reendothelialization
in balloon-injured rat aorta. J Korean Med Sci 2000; 15: 31-6
20- Gennaro G, Menard C, Michaud SE, Rivard A. Age-dependent impairment
of reendothelia- lization after arterial injury: role of vascular endothelial
growth factor. Circulation 2003;107:230-3
21- David H, Holly L, Alexander WC. Local plasminogen activator inhibitor type
1 over expression in rat carotid artery enhances thrombosis and endothelial
regeneration while inhibiting intimal thickening. Arterioscler Thromb Vasc
Biol 2000;20:853-9.
22- McMahon FG, Vargas R, Ryan M, Jet al. Pharmacokinetics and effects of
recombinant human erythropoietin after intravenous and subcutaneous
injections in healty volunteers. Blood 1990;76:1718-22.
23- Macdougall IC, Cavill I, Davies ME, Hutton RD, Coles GA, Williams JD.
Subcutaneous recombinant erythropoietin in the treatment of renal anaemia
in CAPD patients. Contributions to Nephrology 1989;76:219-26.
24- Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ.
Pharmacokinetic and pharmacodynamic modeling of recombinant human
erythropoietin after single and multiple doses in healthy volunteers. J Clin
Pharmacol 2004;44:991-1002
25- Saray A, Ozakpınar R, Koc C, Serel S, Sen Z, Can Z. Effect of chronic
and short-term erythropoietin treatment on random flap survival in rats: an
experimental study. Laryngoscope 2003;113 85-9.
26- Martino MA, Vogel KM, O’Brien SP, Kerstein MD. Erythropoietin therapy
improves graft patency with no increased incidence of thromboses or
thrombophlebitis. J Am Coll Surg 187: 616-619, 1998.
27- Harashina T, Fujino T, Watanabe S. The intimal healing of microvascular
anastomoses. Plast Reconstr Surg 1976;58:608-13.
28- Zhang B, Wieslander JB. Healing of a severe microarterial trauma: an
experimental study. Microsurgery 1994;15:130-40.
29- Walker LN, Ramsay MM, Bowyer DE. Endothelial healing following defined
injury to rabbit aorta. Depth of injury and mode of repair. Atherosclerosis
1983;47:123-30

Thank you for copying data from http://www.arastirmax.com